再鼎医药:H1净亏收窄33.33%,多产品有新进展

和讯网
Aug 08, 2025

【8月8日再鼎医药举行业绩会,回应产品销售、药物短缺及管线进展等问题】 8月8日消息,从半年报看,H1再鼎医药仍亏损,但同比有所收窄。在当日业绩会中,公司管理层介绍部分主要产品销售情况和下半年业绩展望,还回应鼎优乐药物短缺、肿瘤与精神类药物管线进展和商业化布局等问题。 业绩会上,再鼎医药管理层对完成全年业绩指引和四季度盈利目标持乐观态度。称FcRnQ2环比增46%,新患增加和DOT延长是主因,受新...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10